What’s new at PolyPeptide? Things are happening all the time!
If you need more information about our company, you can request our brochures here


Press release

PolyPeptide Group today announced the appointment of Dr. Raymond De Vré as its new Chief Executive Officer. He will succeed Jane Salik who has decided to concentrate on her role on the Board of Directors after 15 very successful years as CEO. Raymond De Vré will join PolyPeptide Group as CEO elect on 1 April 2021 and will work alongside Jane Salik during a transition period prior to taking up his role as CEO over the course of the summer. Jane Salik will remain a member of the Executive Committee until the summer of 2021, after which she will continue to focus on her role on the Board of Directors.

See Press Release


Congratulations Novavax!

PolyPeptide congratulates all at Novavax and its supply chain partners on the news that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). The PolyPeptide Group continues to support Novavax and the NVX-CoV2373 with the production of two key intermediates used in the production of Matrix M™, the adjuvant component of the vaccine.’

See press release from Novavax


PolyPeptide News Flash, #1, 2021

PolyPeptide Group maintained a strong and healthy pipeline that has gained a significant growth in 2020. This growth in Pipeline Projects reflects the growth in peptide therapeutics market and emphasizes the importance of peptides in drug and vaccine development.

Also in this Newsletter "New In-Silico Development Tools Support More Efficient Process Design" and get to know Christelle Bobier, Director Global Engineering and Manufacturing Technology

read more


SPPS 600L reactor

PolyPeptide News Flash, #3, 2020

As a Global Leader in Peptide Manufacturing and Development, the PolyPeptide Group has been actively engaged on projects with clients who are developing peptide-based therapies and vaccines to combat COVID-19. Also in this News Flash, learn more about PolyPeptide's recent capacity expansion through investment and innovation.

read more


Press Release

Press Release: PolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine

The PolyPeptide Group, a global Contract Development and Manufacturing Organization (CDMO) for Peptide, Peptidomimetic and other Drug Substances, has announced that it has partnered with Novavax Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax’ novel coronavirus vaccine candidate, NVX-CoV2373. PolyPeptide Group will produce two key intermediates used in the production of Matrix-M™, the adjuvant component of the vaccine, which is being used to enhance the vaccine’s immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology.

Read the press release



PolyPeptide News Flash, #2, 2020

While the COVID-19 crisis continues, the PolyPeptide Group is actively engaged in helping find treatments and vaccines for COVID-19. See report on promising therapies in our latest Newsletter. We are also highlighting our ongoing Digitalization projects as well as introducing our new Global Director for Quality Control and Analytical Development, Eran Benjamin, read more


Letter covid19

Information Letter on COVID-19

Download letter PDF here


Dear Valued Customer,

While the COVID-19 crisis continues, I want to assure you that the PolyPeptide Group remains ready to support your business. Our sites are operating at almost-full capacity. At the same time, we have put numerous steps in place to protect the health and safety of our employees, including rigorous cleaning and infection control procedures.

Our company is also actively engaged in helping to find treatments and cures for COVID-19. Within the next few weeks, we will have teams at almost all sites working on projects to:

  1. Develop a peptide-based vaccine or vaccine cocktail against the virus

  2. Use peptides as immuno-modulators to allow our own immune system to fight this disease

  3. Use anti-inflammatory peptides to fight the excessive release of cytokines that this disease may cause

  4. Develop entry-inhibiting peptides that may inhibit coronavirus’ ability to enter human lung cells

We would be honored to help further your projects to combat the virus.

Our lines of communication remain open as we work to support your projects, your business, and your patients. Thank you for your ongoing partnership during this challenging time.

Wishing you and your family good health,

Kind regards,


Jane Salik, CEO

Download letter PDF here


MVA Medicona Valley Alliance

New member of the Medicon Valley Alliance

We are happy to inform that the PolyPeptide Group is from now a member of the Medicon Valley Alliance (MVA). It is a non-profit membership organization, the leading life science cluster in Scandinavia and one of the largest in Europe. With this membership, we wish to strengthen our presence, support and knowledge sharing in the region as the global leader in Peptide Development and Manufacturing.


Sign up for PolyPeptide’s Newsletter